Empagliflozin gets PBAC nod for HFpEF
The recommendation for an expanded PBS listing for empagliflozin follows a recent update to the drug's indication.
The PBAC has recommended expanding the PBS listing for empagliflozin to include patients with chronic heart failure and a left ventricular ejection fraction above 40%.
The SGLT-2 inhibitor is already subsidised for heart failure with reduced ejection fraction as an add-on to standard therapy.
